Resources Search

Andrea Schmoll (2015) explores strategies to optimise licensing agreements, covering preparation, key provisions, and compliance with antitrust laws. Highlighting commercial and financial considerations, the presentation emphasises aligning agreements with IP protection, partner evaluation, and…

Mark Anderson (2012) provides guidance on structuring and drafting licence agreements. He addresses key clauses, risk allocation, performance obligations, and financial terms, emphasising precision in defining rights, responsibilities, and liabilities to ensure clarity and mitigate disputes.

Mark Anderson (2012) examines the drafting and negotiation of CTAs. He addresses key issues like regulatory compliance, intellectual property rights, liability, and indemnities, providing practical guidance on balancing stakeholder interests, ensuring clarity, and managing risks in clinical trial…

Mark Anderson (2009) provides detailed guidance on drafting and negotiating CTAs. He covers regulatory compliance, intellectual property, liability, and indemnities, emphasising clear contractual terms to balance stakeholder interests and navigate legal complexities effectively.

Jeremy Philpott (2012) discusses intellectual property strategies, focusing on patents and alternative protections. He explores when to use patents, strategic application considerations, and unregistered IP. Philpott emphasises commercial intentions, timing, and defensibility to maximise IP value…

Jeremy Philpott (2010) discusses leveraging intellectual property to support innovation. He covers strategic use of patents, trademarks, and unregistered IP, stressing the importance of aligning IP decisions with business goals, market timing, and effective resource management for competitive…

Mark Anderson (2010) provides detailed guidance on creating effective agreements. He addresses key issues like funding, intellectual property, liability, and governance structures, emphasising clarity, compliance, and balancing stakeholder interests to optimise collaborative research and…

The 2007 white paper Drug Discovery and Development: Understanding the R&D Process by the Pharmaceutical Research and Manufacturers of America outlines the complex and costly journey of developing new drugs. It emphasises collaboration, rigorous testing, and technological advancements required for…

The Responsible Partnering Guidelines (2009), developed by European institutional organisations, outline principles for effective collaboration and knowledge transfer between public research organisations and industry. It emphasises strategic alignment, IP management, mutual benefit, and…

The OECD Guidelines on Human Biobanks and Genetic Research Databases (2009) provide ethical, legal, and operational principles for managing biobanks. They address governance, participant rights, data protection, and benefit sharing, aiming to balance scientific progress with respect for individual…

The 2004 handbook Guidelines for Teaching Hospitals for Entering into Research Agreements by Danish teaching hospitals and universities provides frameworks for partnerships with private entities. It addresses IP rights, ethical considerations, confidentiality, and publication policies, promoting…

The OECD Guidelines for the Licensing of Genetic Inventions (2006) provide principles and best practices for managing genetic IP in healthcare. The document focuses on innovation promotion, equitable access, IP balance, and collaboration between public and private sectors to optimise healthcare and…

At the moment an invention is disclosed to the Technology Transfer Office (TTO), the totality of information needed for assessing the invention and possibly filing a patent is often distributed over several persons.

Joris Swennen and Sander Van Loock (2013) analyse key challenges in forming consortia. They address IP ownership, co-ownership, background access, and publication, emphasising clear communication, legal certainty, and tailored agreements to balance academic and industry interests effectively.

This free IP Teaching Kit of the EPO provides academic teaching staff with a unique collection of PowerPoint slides, speaking notes and background information on all the main types of intellectual property (IP).

The Lambert Toolkit has been prepared by the Lambert Working Group on Intellectual Property for universities and companies that wish to undertake collaborative research projects with each other.

Joint ownership often arises in connection with collaborative innovation and is of particular relevance to EU-funded programmes, joint ventures and more generally to any research project involving the co-development of intellectual property (IP).

More and more innovation is driven by research collaborations between different entities. Within the context of globalized economy, these research and innovation collaborations are becoming increasingly internationalised.

Though the scale and substance of collaborations varies, a basic understanding of intellectual property rights (IPR) within the Chinese context may help to maximize the success of joint cooperation.

Samples of human biological material are used for many purposes and are of increasing importance as the funders of research, whether public, charitable or commercial, prioritise areas which rely upon access to human biological samples.

PROvendis has its origins in the innovation consulting firm Zenit GmbH. Founded in 1984, ZENIT is a Public Private Partnership owned by the State of North Rhine- Westphalia, a consortium of banks and an association comprising some 180 enterprises.

Founded in 2001 as a wholly-owned subsidiary of the LifeScience Foundation, Ascenion is a technology transfer company focusing on the field of life sciences. It currently serves a total of 23 research institutes and university hospitals all over Germany.

In order to assist its researchers in providing this information, KU Leuven Research & Development (technology transfer office of KU Leuven) has developed a mandatory Patent Inventor Form.

This document starts from the observation that in tandem with rapid advances in biotechnology research having valuable applications for use in healthcare the Canadian technology transfer activity has grown significantly.

This UNICO Practical Guide covers a selection of topics that are relevant to the management of technology transfer (TT) agreements and relationships.

The development of life science technologies typically involve long timelines and stringent regulatory hurdles, which in combination result in a high investment capital need. In contrast, the financial and societal reward can be tremendous in case of success.

The document titled "Checklist for Revising and Amending Material Transfer Agreements" (2020) provides guidelines for reviewing MTAs. It outlines key principles, definitions, and clauses to safeguard intellectual property, ensure compliance with ethical standards, and balance the interests of…

The 2020 document, "Checklist for Revising and Amending Non-Disclosure Agreements," provides detailed guidelines for drafting NDAs. It covers key aspects such as confidentiality scope, usage, governing law, and termination, aiming to safeguard intellectual property and clarify obligations for…